Dyne Therapeutics

Cambridge, United States Founded: 2017 • Age: 9 yrs Listed
Nucleic acid therapies for rare diseases are developed.

About Dyne Therapeutics

Dyne Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2017. Nucleic acid therapies for rare diseases are developed. The company has 191 employees. Its website dyne-tx.com draws about 18 thousand monthly visits. Dyne Therapeutics offers products and services including DYNE-101, DYNE-251, and DYNE-302. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is Dyne Therapeutics, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.

Company details

Dyne Therapeutics was founded in 2017 and is headquartered in Cambridge, United States. Nucleic acid therapies targeted at rare diseases, including muscle disorders such as myotonic dystrophy, are provided by the company. Proprietary technology is utilized for drug discovery and development, with focus areas encompassing linker chemistry and antibiotic engineering. Treatments for various rare genetic conditions are also advanced through these operations in the biotechnology sector.

  • Headquarters Cambridge, United States
  • Employees 191
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website dyne-tx.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Dyne Therapeutics, Inc.
Key Metrics
  • Net Profit
    -$446.21 M (USD)
    -40.58
    as on Dec 31, 2025
  • EBITDA
    -$466.13 M (USD)
    -36.44
    as on Dec 31, 2025
  • Latest Funding Round
    $115.7M (USD), Post-IPO

    Aug 2020

  • Investors
    Citadel

    & 7 more

  • Employee Count
    191

Products & Services of Dyne Therapeutics

Dyne Therapeutics offers a comprehensive portfolio of products and services, including DYNE-101, DYNE-251, and DYNE-302.

DYNE-101
Gene Therapy

Targets DM1 disease to stop progression in neuromuscular patients.

DYNE-251
Gene Therapy

Focuses on DMD disease for improved muscle function.

DYNE-302
Gene Therapy

Addresses FSHD disease to enhance patient outcomes.

Funding Insights of Dyne Therapeutics

  • Total Rounds 2
  • Last Round Post-IPO — $115.7M
  • First Round $50M

    (Apr 2019)

  • Investors Count 8

All 2 funding rounds of Dyne Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2020$115.7MPost-IPO––
Apr 2019$50MPost-IPO––
Valuation history

8 investors in total: 8 institutional.

Investors in Dyne Therapeutics

Dyne Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Atlas Venture and Vida Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Biomedical innovations are transformed into therapies by Vida Ventures.
vidaventures.comBoston, United States
Private equity fund focused on the biotechnology sector
logoscapital.comSan Francisco, United States
Venture capital firm focused on lifescience and healthcare sectors
forbion.comNaarden, Netherlands
Venture capital firm investing in life science and biotechnology sectors
1980atlasventure.comCambridge, United States
Diversified investment management services are provided to institutional clients.
wellington.comBoston, United States
Diversified investment management services are offered in India.
franklintempletonindia.comMumbai, India
Invests in biotech firms developing life-saving drugs and technologies.
mpmcapital.com
Long, short, event-driven, and multiple strategies are employed by Citadel.
1990citadel.comChicago, United States
Premium access

Investor details for Dyne Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Dyne Therapeutics

59 people are tracked at Dyne Therapeutics (45 in leadership, 6 in board & advisors, 8 in team); the tracked headcount is 191.

NameRoleGroup
Robert Ciamarra
Head Of ProcurementLeadership
Lori Ryan
Director, Clinical QualityLeadership
Lucia Celona
Chief Human Resources OfficerLeadership
Oxana Beskrovnaya
Chief Innovation OfficerLeadership
Molly White
VP, Global Head of Patient Advocacy & EngagementLeadership
Ashley Clark
Director, Human ResourcesLeadership
Zachary E. Hurwitz
Director, Head Of Medical WritingLeadership
Lisa Guarino
Director Data ManagementLeadership
Annalyn Gilchrist
Director, New Product PlanningLeadership
Brian Newkirk
Vp, Program Team Leader And Head Of New Product PlanningLeadership
Daniel Wilson
SVP Head Of LegalLeadership
Baoguang Han
Vice President, Head Of BiometricsLeadership
Clarence J. Wang
Vp, Head Of Data SciencesLeadership
Joanne Bryce
Director, FinanceLeadership
Kate Mitchell
VP, Head of Human ResourcesLeadership
Debra Feldman
VP, Head of RegulatoryLeadership
Cong Yao
Executive Director, Intellectual Property Senior CounselLeadership
Bill Schoeninger
Director, External Reporting And AccountingLeadership
Ross Hanson
Senior Director, Head Of Financial Planning & AnalysisLeadership
Iva Ivanovska Holder
Vice President, Global Head, Scientific And Medical CommunicationsLeadership

39 more people are available in the full profile.

Premium access

Complete people profiles for Dyne Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Dyne Therapeutics

Dyne Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DYN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date17 Sep 2020
  • Listed onNASDAQ: DYN
  • Listed entityDyne Therapeutics, Inc.
  • Exchange sectorHealth technology
  • ISINUS26818M1080
  • Share price$15.30 (-4.14% on the day) · 2026-10-13
  • Market capitalisation$2.86B
  • EPS (diluted, trailing year)$-3.33
  • Volume (last session)3,341,604

Financials of Dyne Therapeutics

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025-$446.2M-$466.1M
2024-$317.4M-$341.6M
2023-$235.9M-$239.7M
2022-$168.1M-$167.6M
2021-$149.3M-$148.9M
Premium access

Detailed financial statements for Dyne Therapeutics

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Dyne Therapeutics

4 dated milestones of Dyne Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded Dyne Therapeutics is founded.
  2. Funding First funding round of $50.0M.
  3. Funding Latest funding round, Post-IPO, of $115.7M.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Dyne Therapeutics

Dyne Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
bridgebio.com2015Palo Alto, United States$434.2M
Therapeutics for genetic diseases are developed through targeted interventions.
sparktx.com2013Philadelphia, United States$82.8M822
Gene therapies for rare diseases including retinal dystrophies are developed.
alnylam.com2002Cambridge, United States$17M2,100
RNA interference-based therapeutics are developed for multiple disorders.
Premium access

Detailed competitors of Dyne Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Dyne Therapeutics

The website of Dyne Therapeutics (dyne-tx.com) receives about 18K visits a month and ranks #1,573,169 among all websites worldwide, #2,100 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    18K

    ▲ 12% vs previous month

  • Unique visitors
    6.9K

    per month

  • Global rank
    #1,573,169

    among all websites

  • Category rank
    #2,100

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Dyne Therapeutics. Affinity shows how closely the audiences match.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Dyne Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Dyne Therapeutics

Premium access

Complete news archive for Dyne Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dyne Therapeutics

Dyne Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Dyne Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Dyne Therapeutics has 191 employees.

Dyne Therapeutics was founded in 2017 and is headquartered in Cambridge, United States. Nucleic acid therapies targeted at rare diseases, including muscle disorders such as myotonic dystrophy, are provided by the company. Proprietary technology is utilized for drug discovery and development, with focus areas encompassing linker chemistry and antibiotic engineering. Treatments for various rare genetic conditions are also advanced through these operations in the biotechnology sector.

Dyne Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Alnylam.

Dyne Therapeutics offers DYNE-101, DYNE-251, and DYNE-302.

Yes, Dyne Therapeutics is publicly traded on NASDAQ under the ticker symbol DYN.

Dyne Therapeutics has 8 investors. Key investors include Citadel, Atlas Venture, Vida Ventures, Wellington, and Logos Capital.

Dyne Therapeutics operates through Dyne Therapeutics, Inc..

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available